A live vaccine to Staphylococcus aureus infection

  title={A live vaccine to Staphylococcus aureus infection},
  author={Dane Parker},
  pages={700 - 702}
  • D. Parker
  • Published 21 March 2018
  • Medicine, Biology
  • Virulence
In this issue Moscoso et al [1] present exciting data utilizing a D-alanine mutant of Staphylococcus aureus as a live vaccine against lethal infection. Given the absence of a currently approved vaccine and antibiotic resistance within the S. aureus population it provides new hope in the prevention of this common human pathogen. 

Development of a Conserved Chimeric Vaccine for Induction of Strong Immune Response against Staphylococcus aureus Using Immunoinformatics Approaches

The overall results of the study showed that the designed novel chimeric vaccine can simultaneously elicit humoral and cell-mediated immune responses and is a reliable construct for subsequent in vivo and in vitro studies against the pathogen.

Subtractive proteomic analysis of antigenic extracellular proteins and design a multi‐epitope vaccine against Staphylococcus aureus

The designed vaccine construct VSA‐30 can be developed as an appropriate vaccine to target S. aureus infection and still needs experimental validation to assure the antigenic and immunogenic properties.

Important new therapies for methicillin-resistant Staphylococcus aureus

The efficacy and safety of recently approved anti-MRSA molecules as well as some newer agents currently under investigation are reviewed with a specific focus on the potential role of these drugs in everyday clinical practice.

Epidemiology of Staphylococcus aureus Infections in Kenya: Current State, Gaps and Opportunities

Standardized national surveillance and reporting incorporating molecular tools for identification and characterization will help fill existing gaps in the understanding of the evolving epidemiology of MRSA infections in Kenya.

Recent developments in methicillin- resistant Staphylococcus aureus (MRSA) management and potential antimicrobial alternatives to combat the antibiotic resistance challenge: A review

A brief description of potential antimicrobial alternatives i.e., phytochemicals from plant extracts, bacteriocins, antimicrobial peptides, bacteriaiophage therapy, nanoparticles and some other approaches that can be used as monotherapy or in combination with currently effective antibiotics to combat MRSA infections are provided.

Identification of CD4+ T cell epitopes from Staphylococcus aureus secretome using immunoinformatic prediction and molecular docking

A set of 11 CD4+ T cell epitopes that can be used as vaccine candidates was identified on the basis of the analysis of the strength of binding, non-self presentation in the human host, propensity to bind to a higher number of alleles, and energetically favorable interactions with HLA molecules.

Dangerous Pathogens as a Potential Problem for Public Health

This paper is to present the most dangerous pathogens, as well as general characterizations, mechanisms of action, and treatments, among bacteria and viruses that have a significant impact on public health.

A blood-based comprehensive and systems-level analysis of disease stages, immune regulation and symptoms in COVID-19 patients

The study involving PBMC-based RNA profiling may further help understand complex and variable systems-wide responses displayed by coronavirus-infected patients.

Design, synthesis, and discovery of novel oxindoles bearing 3-heterocycles as species-specific and combinatorial agents in eradicating Staphylococcus species

Novel oxindole compounds directly have lethal action or boost existing antibiotic power with the reduction of doses and toxicity in the treatment of multidrug-resistant Staphylococcus species.

A blood transcriptome-based analysis of disease progression, immune regulation, and symptoms in coronavirus-infected patients

The COVID-engine inferential statistics platform and study involving PBMC-based RNA profiling may help understand complex and variable system-wide responses displayed by coronavirus-infected patients with further validation.



Models matter: the search for an effective Staphylococcus aureus vaccine

It is suggested that an over-reliance on rodent models and a focus on targeting cell surface components have been major contributing factors to this failure of S. aureus vaccine trials.

Challenges for a universal Staphylococcus aureus vaccine.

  • R. Proctor
  • Biology, Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2012
The major new information involves the role of cell-mediated immunity, specifically T-helper 17 cells and interleukin 17, as well as the lack of protection afforded by specific antibodies, which has major implications for future vaccine development and planning of clinical trials.

Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors

This review outlines important considerations in designing a vaccine for the prevention of S. aureus disease in healthcare settings based on multiple important bacterial pathogenesis mechanisms.

Progress toward a Staphylococcus aureus vaccine.

  • R. DaumB. Spellberg
  • Biology, Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2012
Targeting staphylococcal protein A and stimulating the T-helper 17 lymphocyte pathway have each received recent attention as alternative approaches to vaccination in addition to the more traditional identification of opsonophagocytic antibodies.

A D-Alanine auxotrophic live vaccine is effective against lethal infection caused by Staphylococcus aureus

It is concluded that this D-alanine auxotroph protects mice efficiently against virulent staphylococcal strains through the combined action of antibodies and IL-17A, and therefore constitutes a promising vaccine candidate against staphlyococcal disease, for which no licensed vaccine is available yet.

Vaccine Protection of Leukopenic Mice against Staphylococcus aureus Bloodstream Infection

A vaccine with four surface antigens, which was identified by genetic vaccinology using sortase A mutants, raised antigen-specific immune responses that protected leukopenic mice against staphylococcal BSI.

Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis.

In patients receiving hemodialysis, a conjugate vaccine can confer partial immunity against S. aureus bacteremia for approximately 40 weeks, after which protection wanes as antibody levels decrease.

Bacterial Survival Amidst an Immune Onslaught: The Contribution of the Staphylococcus aureus Leukotoxins

The reemerging interest in leukotoxins as potent virulence factors with defined cellular targets, the implications of their lethal and sublethal cellular effects, as well as challenges that have restricted understanding of their functional activity in vivo are discussed, while emphasizing areas of interest for future exploration.